RECRUITING

Effect of TXA on Reducing Bruising After Filler Injection

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection? Participants will receive the study medication along with the standard facial filler injection and complete surveys.

Official Title

Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study

Quick Facts

Study Start:2025-09
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06665594

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age equal to or greater than 18 but less than or equal to 89 years.
  2. * Participants interested in facial filler (HA) injection.
  3. * English speaking.
  1. * Minors or under the age of 18
  2. * Participant over the age of 89
  3. * Pregnant or breast-feeding women
  4. * Individuals unable to give consent due to another condition such as impaired decision-making capacity.
  5. * Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
  6. * Concurrent use of estrogen
  7. * Participants undergoing unilateral facial filler (HA) injection
  8. * Participants with history of hypersensitivity to TXA or any of the other ingredients
  9. * Participants that are on current therapeutic anticoagulation therapy and aspirin use
  10. * Participants with stage 2 or greater renal failure
  11. * Participants on hemo- or peritoneal dialysis
  12. * History of diabetes or seizures
  13. * Current tobacco smokers
  14. * Acquired defective color vision

Contacts and Locations

Study Contact

Armin Edalatpour, MD
CONTACT
608-263-7502
edalatpour@wisc.edu

Principal Investigator

Daniel Cho, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin - Madison
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Daniel Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09
Study Completion Date2026-09

Study Record Updates

Study Start Date2025-09
Study Completion Date2026-09

Terms related to this study

Additional Relevant MeSH Terms

  • Facial Filler Injections
  • Hyaluronic Acid
  • Tranexamic Acid